Comparative Pharmacology
Head-to-head clinical analysis: ACCUPRIL versus AMLODIPINE MALEATE BENAZEPRIL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCUPRIL versus AMLODIPINE MALEATE BENAZEPRIL HYDROCHLORIDE.
ACCUPRIL vs AMLODIPINE MALEATE; BENAZEPRIL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin-converting enzyme (ACE) inhibitor; inhibits ACE, thereby blocking conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. Benazepril is an angiotensin-converting enzyme (ACE) inhibitor that prevents the conversion of angiotensin I to angiotensin II, resulting in vasodilation and reduced aldosterone secretion.
10-40 mg orally once daily; initial dose 10 mg, titrate to target dose based on blood pressure response; maximum 80 mg/day.
Initial: 2.5-5 mg amlodipine / 10-20 mg benazepril orally once daily, titrated to 10/40 mg once daily based on response.
None Documented
None Documented
Quinaprilat terminal elimination half-life is approximately 3 hours. In patients with renal impairment (CrCl <30 mL/min), half-life can be prolonged up to 10-25 hours, requiring dose adjustment.
Amlodipine: 30-50 h (terminal), allowing once-daily dosing; benazeprilat: 10-11 h (terminal), effective for 24 h.
Primarily renal (about 60% as unchanged drug and 40% as metabolites, mainly quinaprilat), with biliary/fecal elimination accounting for less than 10%.
Renal: Amlodipine 10% unchanged, benazeprilat (active metabolite) 50-60% in urine; biliary/fecal: amlodipine 20-25% as metabolites, benazeprilat 10-20% in feces.
Category C
Category D/X
ACE Inhibitor
ACE Inhibitor